No Intraparenchymal Mass Lesion in a Patient with Lung Adenocarcinoma with Treatment-Resistant Seizures: What Next?

Creative Commons License

İNAN B., Kapakl G. E. T., DERİCİOĞLU N.

TURKISH JOURNAL OF NEUROLOGY, cilt.27, sa.2, ss.212-214, 2021 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 27 Sayı: 2
  • Basım Tarihi: 2021
  • Doi Numarası: 10.4274/tnd.2021.94762
  • Dergi Adı: TURKISH JOURNAL OF NEUROLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.212-214
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Leptomeningeal carcinomatosis (LMC) is a relatively rare complication of advanced-stage cancer. The diagnosis of LMC is based on clinical and radiologic findings and cytologic examinations. The diagnosis may be difficult because the clinical findings may be subtle initially, and the specificity of the diagnostic modalities is low. A 41-year-old male patient with metastatic lung adenocarcinoma presented with headache, confusion, and treatment-resistant seizures. There was no intraparenchymal mass lesion or leptomeningeal contrast enhancement in brain magnetic resonance imaging. The presence of LMC was demonstrated in a cytopathologic examination of cerebrospinal fluid. The seizures were controlled with antiepileptic treatment, but the patient was referred to the palliative care center due to poor oncologic prognosis.